Market research
EW Edwards Lifesciences Corp
NYSE USD Healthcare
Latest close
As of 30 Oct 2026
Test a moving-average rule with historical data.
Market facts
- Market cap
- 54B
- P/E ratio
- 56.21
- Analyst target
- 101.867
- Dividend yield
- Not available
- Beta
- 0.86
Profile
Instrument facts
- Exchange
- NYSE
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Devices
- ISIN
- Not available
- Market cap
- 54B
- P/E ratio
- 56.21
- Analyst target
- 101.867
- Dividend yield
- Not available
- Beta
- 0.86
About
About Edwards Lifesciences Corp
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL and EVOQUE brands. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS brand name; INSPIRIS RESILIA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valve conduit for complex combined procedures; and MITRIS RESILIA valve. It distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Research context
Edwards Lifesciences Corp appears in PyInvesting’s US Stock catalogue. The price history above describes this recorded instrument; it does not by itself identify a company’s business or establish a continuous investment return.
- Currency
- USD
- Sector
- Healthcare
- Industry
- Medical Devices
These are the latest stored catalogue classifications, not a historical classification snapshot. An issuer description, classification effective date or currency may be unavailable. Check the issuer’s own disclosures and the observation dates before using these fields for research.
Review backtest assumptions and evidence before treating a chart or stored history as a research result.
Community
Investor discussion
1 comment
Sign in to join the EW discussion.
5 years, 6 months ago
Edwards Lifesciences Corporation is currently in a long term uptrend where the price is trading 23.0% above its 200 day moving average.
From a valuation standpoint, the stock is 99.1% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 12.1.
Edwards Lifesciences Corporation's total revenue rose by 1.5% to $1B since the same quarter in the previous year.
Its net income has increased by 10.5% to $310M since the same quarter in the previous year.
Finally, its free cash flow fell by 12.6% to $286M since the same quarter in the previous year.
Based on the above factors, Edwards Lifesciences Corporation gets an overall score of 4/5.